CYRX - Cryoport, Inc.
7.90 +0.05 (0.64%)
After hours: 4:54PM EDT
| Previous Close | 7.90 |
| Open | 7.88 |
| Bid | 7.85 x 100 |
| Ask | 8.00 x 100 |
| Day's Range | 7.76 - 8.02 |
| 52 Week Range | 1.80 - 10.40 |
| Volume | 105,085 |
| Avg. Volume | 276,069 |
| Market Cap | 195.06M |
| Beta | 1.68 |
| PE Ratio (TTM) | -14.22 |
| EPS (TTM) | -0.55 |
| Earnings Date | Jun 29, 2017 - Jun 30, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.25 |
- Capital Cube•4 days ago
ETFs with exposure to CryoPort, Inc. : October 16, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CryoPort, Inc. Here are 5 ETFs with the largest exposure to CYRX-US. Comparing the performance and risk of CryoPort, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- PR Newswire•15 days ago
Cryoport Biotech Activity Index, "CoBRA Index", Increases 8.6% In Second Quarter of 2017
IRVINE, Calif., Oct. 5, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM"), which quantifies the activity in the development and clinical trials of regenerative therapies in the United States, increased 8.6% to 239 in the second quarter of 2017. The number of clinical trials within the regenerative medicine space has notably increased this year, demonstrating the strength of the current regimen of therapies, and increasing confidence in their commercialization prospects. The overall number of trials in the regenerative market increased from 855 to 899. During the second quarter of 2017, approximately $2.45 billion was invested in the development of regenerative therapies, an 88% increase from the second quarter of 2016. The CoBRA IndexSM observed that several late stage clinical trials slowed or paused patient dosing in preparation for commercial launch and/or were compiling data for Biologics License Applications (BLA) filings.
- Capital Cube•18 days ago
ETFs with exposure to CryoPort, Inc. : October 2, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CryoPort, Inc. Here are 5 ETFs with the largest exposure to CYRX-US. Comparing the performance and risk of CryoPort, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- PR Newswire•18 days ago
Cryoport to Provide Nohla Therapeutics with Cutting Edge Cold Chain Logistics to Support Clinical Programs
IRVINE, Calif. , Oct. 2, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today ...
- Capital Cube•last month
ETFs with exposure to CryoPort, Inc. : September 19, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CryoPort, Inc. Here are 5 ETFs with the largest exposure to CYRX-US. Comparing the performance and risk of CryoPort, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Capital Cube•last monthCryoPort, Inc. :CYRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
Categories: Yahoo FinanceGet free summary analysis CryoPort, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of CryoPort, Inc. – General Finance Corporation, Wesco Aircraft Holdings, Inc and Greif Class A (GFN-US, WAIR-US and GEF-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)
- PR Newswire•last month
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel
IRVINE, Calif., Sept. 5, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), today announced that Kite Pharma has chosen Cryoport's industry-leading, advanced technology suite of cryogenic logistics solutions for the life sciences industry to support the potential commercial launch of its lead chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel), for the treatment of aggressive Non-Hodgkin Lymphoma (NHL). The engagement is structured to support Kite throughout the lifecycle of axi-cel. Under the terms of the agreement, Cryoport will provide logistics support throughout the United States in accordance with Kite's plans for patient adoption of axi-cel. Cryoport's advanced cryogenic logistics solutions are designed to meet all of Kite's expanding cryogenic logistics requirements, including the use of its Cryoport Express® shippers, SmartPak II™ Condition Monitoring System, Cryoportal™ logistics platform, which includes chain-of-condition and chain-of-custody monitoring and, 24/7 logistics support.
- MarketWatch•last month
Novartis’ CAR-T therapy was the first approved in U.S. — here’s how to invest in the space
How to get in on “the very early innings” of a growth cycle that could last a decade.
- Zacks Small Cap Research•2 months ago
CYRX: Raising Price Target on CAR-T Opportunity
Cryoport (CYRX) reported Q2 2017 financial results. Results continue to impress as revenue set another new high, extending that streak to 11 straight quarters. Consistent increases in the number of clinical trials that the company supports remains the major catalyst to the topline growth. That metric (i.e. Q2 revenue, at $2.9M, was up 52% yoy and inline with our $2.9M estimate. It is also a new record and up almost 8% sequentially from Q1 (the prior best). This is the fifth consecutive quarter in which revenue came in slightly better and operating loss much better than our respective estimates. The $60k revenue difference in Q2 compared to our estimate relates to $36k beat ($2.22M A vs. $2.19M) in biopharma and $25k ($426k A vs. $401k E) beat in reproductive medicine, partially offset by $20k miss ($263k A vs. $283k E) in animal health.
- PR Newswire•2 months ago
Cryoport Launches - Cryoport. Certified. Cool.
Cryoport. Certified. Cool. solution is designed to provide cold-chain logistics in the 2 - 8 degrees Celsius temperature range for regenerative therapy requirements IRVINE, Calif. , Aug. 15, 2017 /PRNewswire/ ...
- PR Newswire•2 months ago
Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma
Biopharma revenue up 69% year-over-year; 33 new clinical trials supported during second quarter IRVINE, Calif. , Aug. 8, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic ...
- Capital Cube•3 months ago
ETFs with exposure to CryoPort, Inc. : August 4, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CryoPort, Inc. Here are 5 ETFs with the largest exposure to CYRX-US. Comparing the performance and risk of CryoPort, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- ACCESSWIRE•3 months ago
Featured Company News – Novartis Ropes in Cryoport for a Three-Year Contract to Provide Cryogenic Logistics Support for Commercialization of CTL019/CD19 CAR-T Cell Therapy
LONDON, UK / ACCESSWIRE / July 27, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cryoport, Inc. (NASDAQ: CYRX ), following which we have published ...
- PR Newswire•3 months ago
Cryoport to Support Launch of Potential Treatment for Relapsed/Refractory Acute Lymphoblastic Leukemia
IRVINE, Calif., July 25, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), today announced that Novartis has signed an agreement contracting Cryoport over an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy. On March 29th, 2017 Novartis announced that the FDA had accepted their first Biologics License Application for CTL019 and that it was also granted priority review by the FDA. Today, Novartis selected Cryoport for its clinical and commercial logistics support.
- PR Newswire•3 months ago
Cryoport to Report Second Quarter 2017 Financial Results on August 8th, 2017
IRVINE, Calif., July 24, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 after U.S. markets close. Cryoport's senior management will discuss the financial results, review recent corporate developments and provide a general business outlook. The Company will host a conference call at 4:30 pm ET on August 8, 2017 to review its financial results and business outlook. Participants should call 1-877-407-9716 (United States) or 1-201-493-6779 (International) and request the "Cryoport call." A live audio webcast of the call will also be available on the Investor Relations section of the Company's website at www.cryoport.com or at this link.
Capital Cube•3 months agoCryoPort, Inc. :CYRX-US: Earnings Analysis: Q1, 2017 By the Numbers : July 21, 2017
Categories: Yahoo FinanceGet free summary analysis CryoPort, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CryoPort, Inc. – Greif Class A (GEF-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 2.71 million, Net Earnings of USD -1.79 million. Gross ... Read more (Read more...)
- Zacks Small Cap Research•3 months ago
FDA Panel Votes To Approve CTL019, Positive Implications for CYRX
Last week an FDA advisory panel voted unanimously (10-0) to approve CTL019 (tisagenlecleucel-T), a novel CAR-T cell immunotherapy developed by Novartis (NVS), for the treatment of children and young adults (ages 3 - 25) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). B-cell ALL is a form of Leukemia (i.e.
- PR Newswire•3 months ago
Cryoport Continues to Strengthen Sales Team with Appointments of Colin Coffua as Vice President, Strategic Accounts and John Phillips as Executive Director, Consulting Services
IRVINE, Calif., July 13, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced it has strengthened its sales team with the appointments of Colin Coffua as Vice President, Strategic Accounts and John Phillips as Executive Director, Consulting Services. Colin Coffua, an industry veteran with 37 years experience in pharmaceutical related sales and marketing, will drive sales efforts for Cryoport's key strategic account initiatives including key biopharmaceutical companies and clinical research organizations.
- PR Newswire•4 months ago
Cryoport Biotech Activity Index "CoBRA Index" increases 30.1% in Q1 2017
IRVINE, Calif., June 19, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of regenerative therapies in the United States, and acts as a means by which investors, the media and industry participants can evaluate investment in the space. The CoBRA IndexSM was launched in February by Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cold chain logistics solutions provider dedicated to the life sciences industry. The CoBRA IndexSM increased 30.1% to 220 in the first quarter of 2017. This compares favorably to 4.4% growth of the index in Q4, 2016. The leveling off of the CoBRA IndexSM reported in Q4, 2016 appears to have been temporary as existing clinical trial activity has notably increased, which demonstrates the strength of the current pipline of therapies, as well as increasing confidence in their commercialization prospects.
- PR Newswire•4 months ago
Cryoport Expands Agreement with Sanaria to Support Grant Awards with U.S. National Institutes of Health and U.S. Army
IRVINE, Calif., June 7, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company dedicated to the life sciences industry, announces that it will assist ...
- Zacks Small Cap Research•5 months ago
CYRX: Biopharma, Clinical Trial Growth, Fuels Another Record Quarter
By Brian Marckx, CFA NASDAQ:CYRX Q1 2017: Biopharma, Clinical Trials Growth, Fuels Another Record Quarter… Cryoport (NASDAQ:CYRX) reported Q1 2017 financial results for the period ending March 31st. At ...
- PR Newswire•6 months ago
Cryoport Revenue Grows by 74%, Driven by Biopharma
IRVINE, Calif., May 4, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced financial results ...
- Accesswire•6 months ago
Investor Network: Cryoport, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 4, 2017 / Cryoport, Inc. (NASDAQ: CYRX ) (NASDAQ: CYRXW ) will be discussing their earnings results in their Q1 Earnings Call to be held May 4, 2017 at 4:30 PM Eastern Time. ...
- PR Newswire•6 months ago
Cryoport to Report First Quarter 2017 Financial Results on May 4th, 2017
IRVINE, Calif., April 24, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today ...